Компания Kitsa внедряет ИИ-агентов для сокращения сроков клинических исследований вдвое

Kitsa is a healthtech company powering the world's largest clinical research network with AI agents that automate clinical trial processes. It streamlines protocol drafting, site selection across 100+ countries and patient pre-screening using FHIR-based EHR integrations. This cuts study timelines by months for sponsors and CROs. Kitsa exists to cut the ten-year drug development timeline in half by eliminating the operational waste that slows it down. Kitsa is an AI-first clinical research infrastructure company built on a simple observation. “Most of what slows a clinical trial has nothing to do with research. It is manual work, misaligned incentives and coordination failures that consume time without improving outcomes,” Ajay Nyamati, Co-founder and CEO. That is where Kitsa operates. The Problem Is Structural How do structural inefficiencies impact cost, coordination, and data quality in clinical trials? Three failures define how clinical trials run today. First, up to 40 percent of trial spend disappears before the first patient is enrolled, absorbed by manual handoffs among sponsors, CROs, principal investigators and key opinion leaders, where coordination is inherently slow. Second, CROs charge by time and material. Pharma runs against the clock. Those incentives do not align. Third, patient data sourced from EHRs can be years old by the time it reaches researchers, limiting the quality of decisions that follow. Data mobility, once a hard constraint, is largely solved. Cloud infrastructure and standardization have made data movement fluid. LLMs can now automate coordination tasks that previously required human effort. Kitsa was built to occupy that opening, combining AI infrastructure, a proprietary data layer and domain expertise inside a services-software model that ties revenue to outcomes. Where the Work Happens Why is the pre-enrollment phase critical for accelerating clinical trial timelines and outcomes? Kitsa focuses on the period before the first patient is enrolled, where bad decisions cost the most and good ones accelerate everything that follows. Protocol development is the starting point. A protocol is the foundation of any trial. Errors cascade into recruitment failures, FDA amendments and approval delays. Yet most protocols are still written ad hoc, with quality varying by budget and team and collaboration happening over emailed Word documents. For an industry where IP is the primary competitive differentiator, that process carries serious risk. KScribe Clinical Document Studio replaces it. Research, collaboration, simulation and document generation happen inside a single secure, regulatory-compliant environment. Purpose-trained LLMs and curated domain data raise output quality regardless of team experience. What took 6 to 12 months now takes weeks. Site selection runs through Kitsa.com, a global discovery platform with the largest listing of clinical trial sites (500,000+), replacing the Rolodex with data-driven matching across active clinical sites worldwide. Patient identification runs through KScreener, which applies fine-tuned LLMs directly to surface eligible participants in minutes. Proof in Practice In what way does Kitsa demonstrate efficiency gains through real-world clinical trial examples? A MedTech company spent six to seven months trying to produce a workable protocol. It found an expert, wrote a draft, received FDA objections and burned months trying to resolve them, still without an outcome. Kitsa generated a draft in two days. When the client reviewed it, they asked how Kitsa had addressed the exact FDA objections they had received, objections they had never disclosed. The platform had anticipated them independently. Within a month, the client had a finalized, regulatory-aligned protocol. What had consumed the better part of a year was done in weeks, with higher quality and without the rework. Most of what slows a clinical trial has nothing to do with research. It is manual work, misaligned incentives and coordination failures that consume time without improving outcomes. Kitsa is evolving Kitsa.com into the world’s largest collaboration network for clinical research. In the agentic AI era, building capabilities is no longer the differentiator. The winner is whoever reaches the most stakeholders with the least friction. Distribution is the moat. Nyamati brings 12 years in pharma and life sciences. His co-founder brings 20. Both come from Amazon Web Services, where they saw the power of LLMs early and recognized that the opportunity was not to patch existing processes but to rebuild them. “Real differentiation lies in how you take it to a complete, production-ready outcome. That is where our workflows and domain expertise come into play,” says Nyamati. Kitsa is building toward a marketplace where sponsors, sites and other stakeholders connect and execute on one platform. The infrastructure is in place. The network is growing. The goal stays the same: fewer years between discovery and the patients a trial is meant to reach. Harnessing Digital Transformation for Business Growth and Innovation Indian-Led Companies in the US Info What Are Companies Founded/Managed by Indians in the US, and What Do They Contribute? Companies Founded/Managed by Indians in the US operate across technology, healthcare, financial services and other fields. Many combine specialized knowledge with technology to solve business needs. In healthcare, they can help address gaps in research and patient access. Kitsa, for example, uses artificial intelligence in clinical research to automate patient pre-screening and connect trial sites with opportunities. Companies Founded/Managed by Indians in the US can therefore offer focused solutions to complex industry needs. How Do Companies Founded/Managed by Indians in the US Apply Technology to Industry Challenges? Technology can turn time-consuming processes into more structured workflows. In clinical research, this can include analyzing electronic health record data, matching patients with study requirements and improving access to trial opportunities. Kitsa uses AI agents across clinical trial processes and supports EHR-based workflows. Its platform includes tools for protocol generation, site selection and patient screening. What Should Organizations Look For When Evaluating Companies in This Category? Organizations should look beyond a technology label and examine how a solution fits an existing workflow. Relevant factors include data integration, transparency, ease of implementation, scalability and measurable improvements. For clinical research, buyers may also consider whether a platform can work with existing EHR systems, handle eligibility criteria accurately and provide traceable reasons for patient matches. These considerations help organizations assess Companies Founded/Managed by Indians in the US based on practical capability. How Can AI Improve Clinical Trial Recruitment and Screening? AI can reduce the manual effort involved in reviewing patient records and identifying potential trial participants. Effective systems can evaluate multiple eligibility criteria, work with structured and unstructured health data and provide explanations for matching decisions. Kitsa uses AI-powered screening that evaluates patients across more than 50 criteria, while its traceability features connect selections to information such as vitals, medications and visit summaries. This approach can help Companies Founded/Managed by Indians in the US deliver technology that addresses specific operational constraints. What Role Does Kitsa Play Among Companies Founded/Managed by Indians in the US? Kitsa focuses on clinical research and uses AI to automate parts of trial operations. Its platform supports patient screening, site selection and protocol-related workflows, while its marketplace connects research sites with pharmaceutical sponsors. Kitsa also supports secure, compliant referrals and integrates with existing EHR systems. Its focus on reducing manual screening and accelerating recruitment places clinical trial operations at the center of its technology model. Why Does Faster Clinical Trial Execution Matter for Research Organizations? Clinical trials depend on timely recruitment, accurate screening and coordinated site activity. Delays can extend study timelines and increase the administrative burden on research teams. Companies Founded/Managed by Indians in the US working in this space can help address these pressures by applying automation to specific stages of the research process. Kitsa's platform is designed to reduce screening failures, save manual effort and support faster recruitment, showing how targeted technology can contribute to more efficient clinical research operations.